…
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Acura Pharmaceuticals is a small specialty pharmaceutical company that develops and licenses formulations intended to deter drug abuse and tampering, including a pseudoephedrine product designed to resist extraction for illicit methamphetamine production. Long-term growth may be driven by licensing agreements, commercial adoption of abuse-deterrent products, and regulatory focus on reducing diversion. Investors may find the company attractive because it appears positioned to monetize intellectual property through partnerships rather than large manufacturing operations.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Income before tax | -0.88M | -1.21M | -3.77M | -3.84M | -5.82M |
| Net income | -0.88M | -1.21M | -3.77M | -3.84M | -5.68M |
| Selling general administrative | 1.25M | 2.55M | 1.88M | 2.57M | 4.34M |
| Gross profit | - | 3.57M | 2.66M | 0.41M | 2.84M |
| Reconciled depreciation | 0.09M | 0.12M | 0.27M | 0.28M | 0.29M |
| Ebit | - | -0.76M | -3.33M | -3.62M | -5.22M |
| Ebitda | -0.68M | -0.63M | -3.04M | -3.17M | -4.93M |
| Non operating income net other | - | - | -2.60M | 0.30M | 0.00M |
| Operating income | -1.21M | -0.76M | -0.72M | -3.92M | -5.22M |
| Interest expense | 0.20M | 0.45M | 0.46M | 0.40M | 0.00M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | -0.14M |
| Interest income | - | 0.00M | 0.01M | 0.17M | 0.00M |
| Net interest income | -0.20M | -0.45M | -0.45M | -0.22M | -0.59M |
| Income tax expense | - | - | - | - | -0.14M |
| Total revenue | 1.56M | 3.57M | 2.66M | 0.41M | 2.97M |
| Total operating expenses | 2.78M | 4.33M | -3.38M | 4.33M | 8.06M |
| Cost of revenue | - | - | - | 0.00M | 0.13M |
| Total other income expense net | 0.54M | - | -2.60M | 0.30M | -0.59M |
| Net income from continuing ops | -0.88M | -1.21M | -3.77M | -3.84M | -5.68M |
| Net income applicable to common shares | - | -1.21M | -3.77M | -3.84M | -5.68M |
| Breakdown | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Total assets | 0.86M | 1.74M | 2.56M | 2.15M | 4.60M |
| Intangible assets | - | 0.07M | 0.81M | 1.02M | 1.22M |
| Other current assets | 0.15M | 1.18M | 1.14M | 0.39M | 0.35M |
| Total liab | 0.68M | 7.63M | 7.30M | 5.77M | 4.63M |
| Total stockholder equity | 0.18M | -5.89M | -4.74M | -3.62M | -0.03M |
| Other current liab | 0.52M | 0.70M | 0.25M | 0.23M | 0.29M |
| Common stock | - | 0.22M | 0.21M | 0.21M | 0.21M |
| Capital stock | 0.65M | 0.22M | 0.21M | 0.21M | - |
| Retained earnings | -390.08M | -389.20M | -388.00M | -384.22M | -380.38M |
| Other liab | - | - | 0.23M | 0.11M | - |
| Other assets | - | - | 0.03M | 0.07M | 0.14M |
| Cash | 0.07M | 0.41M | 0.86M | 0.09M | 2.22M |
| Total current liabilities | 0.52M | 7.52M | 1.07M | 1.44M | 4.63M |
| Net debt | 0.15M | 5.86M | 5.14M | 4.13M | 0.47M |
| Short term debt | - | 6.16M | - | - | 2.69M |
| Short long term debt | - | 6.16M | - | - | 2.69M |
| Property plant equipment | - | 0.48M | 0.54M | 0.61M | 0.68M |
| Total current assets | 0.37M | 1.18M | 1.18M | 0.46M | 2.57M |
| Long term investments | - | - | 0.03M | 0.07M | 0.14M |
| Net tangible assets | - | -5.96M | -5.55M | -4.63M | -1.25M |
| Net receivables | 0.16M | 0.63M | 0.03M | 0.07M | 0.07M |
| Long term debt | 0.15M | 0.10M | 6.00M | 4.22M | - |
| Inventory | - | - | - | - | 0.00M |
| Accounts payable | 0.19M | 0.66M | 0.82M | 1.20M | 1.64M |
| Common stock total equity | - | 0.22M | 0.21M | 0.21M | 0.21M |
| Retained earnings total equity | - | -389.20M | -388.00M | -384.22M | -380.38M |
| Non currrent assets other | 0.05M | - | 0.84M | 1.08M | 1.36M |
| Non current assets total | 0.49M | 0.56M | 1.38M | 1.69M | 2.04M |
| Capital lease obligations | 0.05M | - | - | - | - |
| Long term debt total | - | - | 6.00M | - | - |
| Breakdown | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Investments | - | - | - | 0.00M | 0.31M |
| Change to liabilities | - | -0.37M | -0.36M | -0.34M | 0.23M |
| Total cashflows from investing activities | - | - | - | - | 0.31M |
| Net borrowings | - | 0.27M | 1.38M | 1.78M | -2.76M |
| Total cash from financing activities | 0.39M | 0.27M | 1.39M | 1.78M | 1.24M |
| Change to operating activities | - | 0.49M | 0.45M | -0.72M | 0.29M |
| Net income | -0.88M | -1.21M | -3.77M | -3.84M | -5.68M |
| Change in cash | -0.35M | -0.45M | 0.77M | -2.13M | -2.96M |
| Begin period cash flow | 0.41M | 0.86M | 0.09M | 2.22M | 5.18M |
| End period cash flow | 0.07M | 0.41M | 0.86M | 0.09M | 2.22M |
| Total cash from operating activities | -0.74M | -0.72M | -0.62M | -3.91M | -4.51M |
| Issuance of capital stock | 0.00M | 0.00M | 0.01M | 0.00M | - |
| Depreciation | 0.09M | 0.12M | 0.34M | 0.37M | 0.39M |
| Other cashflows from investing activities | - | - | - | - | 0.31M |
| Change to inventory | - | - | - | 0.00M | 0.10M |
| Change to account receivables | - | -0.47M | -0.02M | -0.07M | 0.02M |
| Sale purchase of stock | - | - | - | - | 4.00M |
| Other cashflows from financing activities | - | 0.00M | 0.01M | 0.00M | - |
| Change to netincome | - | 0.70M | 2.71M | -0.08M | 0.46M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change receivables | - | - | - | - | 0.02M |
| Cash flows other operating | - | 0.03M | 0.47M | -0.02M | -0.04M |
| Cash and cash equivalents changes | - | -0.45M | 0.77M | -2.13M | -2.96M |
| Change in working capital | 0.48M | -0.34M | 0.12M | -0.18M | 0.27M |
| Stock based compensation | 0.06M | 0.04M | 0.11M | - | - |
| Other non cash items | - | -0.22M | 0.05M | -0.09M | 0.10M |
| Free cash flow | -0.74M | -0.72M | -0.62M | -3.91M | -4.51M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ACUR Acura Pharmaceuticals Inc |
- -% |
0.00 | - | - | 0.10 | 0.85 | 0.18 | -4.61 |
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert B. Jones | CEO, Pres & Director | 1959 |
| Mr. Peter A. Clemens | Sr. VP, CFO & Sec. | 1953 |
| Dr. Albert W. Brzeczko Ph.D. | VP of Pharmaceutical Sciences of Acura Pharmaceutical Technologies, Inc. | 1957 |
| Mr. Robert A. Seiser CPA, Ph.D. | VP, Treasurer & Corp. Controller | 1964 |
| Mr. Robert B. Jones | CEO, President & Director | 1959 |
| Mr. Robert A. Seiser CPA, Ph.D. | CFO, Senior VP, Treasurer & Corporate Controller | 1964 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.